Embecta (NASDAQ:EMBC – Get Free Report) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 2.300-2.350 for the period, compared to the consensus estimate of 2.280. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Embecta also updated its FY24 guidance to $2.30-2.35 EPS.
Embecta Stock Performance
Shares of NASDAQ EMBC opened at $15.39 on Monday. The firm’s 50 day moving average price is $13.35 and its 200-day moving average price is $13.35. Embecta has a 52-week low of $9.93 and a 52-week high of $22.16. The company has a market cap of $887.54 million, a PE ratio of 12.72 and a beta of 0.99.
Embecta (NASDAQ:EMBC – Get Free Report) last issued its quarterly earnings data on Friday, August 9th. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.26. The firm had revenue of $272.50 million for the quarter, compared to analysts’ expectations of $267.44 million. Embecta had a net margin of 6.20% and a negative return on equity of 18.42%. The business’s quarterly revenue was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.69 EPS. On average, analysts forecast that Embecta will post 2.29 earnings per share for the current fiscal year.
Embecta Dividend Announcement
Analyst Upgrades and Downgrades
Separately, Morgan Stanley decreased their target price on Embecta from $13.00 to $12.00 and set an underweight rating on the stock in a report on Monday, July 15th.
View Our Latest Research Report on Embecta
Embecta Company Profile
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Featured Articles
- Five stocks we like better than Embecta
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Stocks with Unusual Trading Volume During Market Selloff
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Fortinet Surges as Cybersecurity Demand Drives Record Earnings
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Top 3 Stocks Bank of America Analysts Recommend Right Now
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.